Aurinia Pharmaceuticals AUPH Business Segments
| TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | TTM Q4 '24 | ||
|---|---|---|---|---|---|---|
| Concentration risk percentage by Product | ||||||
| Collaboration partnership | 7%-1.0pp | 8%-1.0pp | 9%-1.0pp | 10%-1.0pp | 11%+0.3pp | |
| Specialty pharmacy A | 49%0.0pp | 49%0.0pp | 49%0.0pp | 49%0.0pp | 49%-0.5pp | |
| Specialty pharmacy B | 38%-0.2pp | 38.2%-0.3pp | 38.5%-0.2pp | 38.7%-0.3pp | 39%-0.3pp | |
| Revenue by Geography | ||||||
| Japan | $19.21M-7.0% | $20.67M-6.6% | $22.13M-6.2% | $23.58M-5.8% | $25.04M+8.1% | |
| U.S. | $263.84M+5.4% | $250.4M+5.7% | $236.97M+6.0% | $223.53M+6.4% | $210.1M+6.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Aurinia Pharmaceuticals break its business down?
- Aurinia Pharmaceuticals (AUPH) reports concentration risk percentage by product across 3 parts — Collaboration partnership, Specialty pharmacy A and Specialty pharmacy B. Each is extracted from the segment footnotes and tracked over time.
- Where does Aurinia Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Aurinia Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.